ABSTRACT: Pre-eclampsia is a common obstetric complication globally responsible for a significant burden of maternal and perinatal morbidity and mortality. Central to its pathophysiology is the anti-angiogenic protein, soluble fms-like tyrosine kinase-1 (sFLT-1). sFLT-1 is released from a range of tissues into the circulation, where it antagonizes the activity of vascular endothelial growth factor and placental growth factor leading to endothelial dysfunction. It is this widespread endothelial dysfunction that produces the clinical features of preeclampsia including hypertension and proteinuria. There are multiple splice variants of sFLT-1. One, known as sFLT-1 e15a, evolved quite recently and is only present in humans and higher order primates. This sFLT-1 variant is also the main sFLT-1 secreted from the placenta. Recent work has shown that sFLT-1 e15a is significantly elevated in the placenta and circulation of women with pre-eclampsia. It is also biologically active, capable of causing endothelial dysfunction and the end-organ dysfunction seen in pre-eclampsia. Indeed, the over-expression of sFLT-1 e15a in mice recapitulates the pre-eclamptic phenotype in pregnancy. Therefore, here we propose that sFLT-1 e15a may be the sFLT-1 variant primarily responsible for pre-eclampsia, a uniquely human disease. Furthermore, this placental-specific sFLT-1 variant provides promise for use as an accurate biomarker in the prediction or diagnosis of pre-eclampsia.
Introduction
Pre-eclampsia is a common complication of pregnancy, affecting 5-8% of all pregnancies. It is a major contributor to global maternal and perinatal morbidity and mortality, leading to~60 000 direct maternal deaths and~500 000 perinatal deaths annually (WHO, 2005) . Preeclampsia is a clinical diagnosis, whereby a mother develops high blood pressure and evidence of other end-organ disease, such as renal, liver, haematological, respiratory, cerebral or fetoplacental impairment (Mol et al., 2016) . Indeed, this heterogeneity in presentation is reflected in the broad criteria used for its diagnosis (Tranquilli et al., 2014) .
The underlying pathophysiology of pre-eclampsia is still incompletely understood. Early-onset disease (seen at <34 weeks gestation) is thought to relate to abnormally shallow placental invasion leading to persisting placental hypoxia and reperfusion injuries that increase oxidative stress within the placenta (Steegers et al., 2010; Myatt and Roberts, 2015) . In comparison, late-onset pre-eclampsia is thought to relate to underlying maternal endothelial and vascular disease (Steegers et al., 2010; Myatt and Roberts, 2015) . In both situations, the clinical features of disease still likely result from the effects of circulating anti-angiogenic factors released from the placenta.
Since 1694, the release of such a factor(s) from the uterus or placenta into the mother's circulation to cause pre-eclampsia has been postulated (Chesley, 1984) . While many candidate toxins have been proposed, none had been able to experimentally reproduce the complete pre-eclamptic phenotype in vivo when administered to animals: that was until the finding that over-expression of soluble fms-like tyrosine kinase-1 (sFLT-1) could produce a pre-eclamptic phenotype in pregnant rats (Maynard et al., 2003) . This breakthrough discovery initiated a decade of subsequent research, which has firmly cemented a major role for sFLT-1 in the pathogenesis of pre-eclampsia.
sFLT-1 comprises the extracellular domains of the vascular endothelial growth factor receptor-1 (VEGFR-1), and is soluble, being present in the circulation. It acts as an anti-angiogenic protein by antagonizing the actions of both vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Multiple splice variants of sFLT-1 have been described (Sela et al., 2008; Heydarian et al., 2009; Thomas et al., 2009) . These have significantly different tissue distributions (Jebbink et al., 2011) , raising the potential for different physiological and pathological roles. For example, in humans, the main sFLT-1 variant, known as sFLT-1 i13, is widely expressed in most tissues, whereas another variant known as sFLT-1 e15a appears to be almost exclusively expressed by the placenta (Jebbink et al., 2011) .
Ongoing progression in the understanding of the pathophysiology of pre-eclampsia is critical to assisting in improving the clinical care for affected women. Through better understanding, improved approaches for disease prediction, diagnosis and therapies can be developed. Indeed, the identification of a placental-specific sFLT-1 variant holds promise for better prediction and diagnosis of pre-eclampsia.
sFLT-1 and pre-eclampsia
The placenta is central to the development of pre-eclampsia. Indeed, conditions with an increased placental mass, such as multiple and molar pregnancies, carry an elevated risk for pre-eclampsia. Both conditions have been shown to significantly increase sFLT-1 expression (Bdolah et al., 2008; Kanter et al., 2010; Koga et al., 2010) . Indeed, most women with pre-eclampsia have significantly increased levels of sFLT-1 present in their circulation (Levine et al., 2004; Shibata et al., 2005; Levine et al., 2006; Palmer et al., 2015; Souders et al., 2015) with levels dramatically falling within the 48 hours following delivery (Chaiworapongsa et al., 2004; McKeeman et al., 2004) supporting the notion that the placenta is the major source of sFLT-1 in preeclampsia. However, despite the strong evidence that elevated levels of sFLT-1 are associated with pre-eclampsia, this is not uniformly seen in all established cases of pre-eclampsia (Levine et al., 2004; Powers et al., 2005; Palmer et al., 2016a) . This potentially relates to the heterogeneity of mechanisms via which pre-eclampsia may occur.
Early-onset pre-eclampsia is predominately thought of as a placental disease due to poor placental implantation (Steegers et al., 2010) , while late-onset pre-eclampsia likely relates to pre-existing maternal endothelial dysfunction (Ness and Roberts, 1996; Raymond and Peterson, 2011; Myatt and Roberts, 2015) . A postulated explanation is the existence of an endothelial threshold for angiogenic factors. When levels of sFLT-1 surpass this threshold, the net reduction in angiogenic factors (VEGF and PlGF) leads to endothelial dysfunction and the clinical presentation of pre-eclampsia (Maynard et al., 2003; Sugimoto et al., 2003; Ahmad and Ahmed, 2004) . In women with pre-existing endothelial dysfunction (such as hypertension, obesity or diabetes) this threshold is lowered, with less sFLT-1 required to produce the disease state (Levine et al., 2006; Suwaki et al., 2006) . In these circumstances, the normal gestational rise that occurs in sFLT-1 (Levine et al., 2004; Maynard et al., 2013; Palmer et al., 2015) may be enough for preeclampsia to develop, although no significant increase in circulating sFLT-1 during pregnancy is evident (Palmer et al., 2016a) .
Total VEGF levels are also increased in pre-eclamptic pregnancies (Clark et al., 1998; McKeeman et al., 2004) due to underlying placental hypoxia. However, the amount of free, bioavailable VEGF is reduced (Livingston et al., 2000; Maynard et al., 2003; Levine et al., 2004) due to the greater concomitant rise in VEGF binding proteins, such as sFLT-1. This was highlighted by Maynard et al. (2003) , who demonstrated an inversely proportional association between the levels of sFLT-1 in the serum of pre-eclamptic women and serum concentrations of VEGF and PlGF. They also demonstrated the impact of an altered angiogenic balance on endothelial cell function. Their work showed that human umbilical vein endothelial cells (HUVECs) exposed to pre-eclamptic serum failed to form tubular structures (Maynard et al., 2003) , suggesting the presence of an anti-angiogenic factor within the patient serum. Adding exogenous VEGF and PlGF to the preeclamptic serum reversed this effect, further supporting this premise. This was confirmed, as serum from healthy pregnant women induced endothelial tube formation, an effect that was inhibited by the addition of exogenous sFLT-1. The final confirmation of the involvement of sFLT-1 in pre-eclampsia came with the adenoviral over-expression of sFLT-1 in pregnant rats. This produced a pre-eclamptic-like phenotype of hypertension, proteinuria and glomerular endotheliosis (Maynard et al., 2003) . Importantly, these findings confirm that sFLT-1 alone is capable of producing endothelial dysfunction. This work has subsequently been independently validated with sFLT-1 over-expression producing a pre-eclamptic phenotype in animal models (Gilbert et al., 2007; Makris et al., 2007; Bergmann et al., 2010; Kumasawa et al., 2011) .
In humans, sFLT-1 is significantly up-regulated within both placenta and blood of women with pre-eclampsia (Ahmad and Ahmed, 2004; Chaiworapongsa et al., 2004; Levine et al., 2004; McKeeman et al., 2004; Powers et al., 2005) , as is the placental-specific variant (Palmer et al., 2015; Souders et al., 2015) . Importantly, when sFLT-1 is removed by either immunoprecipitation or apheresis, the proangiogenic capabilities of the serum are restored (Ahmad and Ahmed, 2004) and the clinical phenotype in pregnant women stabilized (Thadhani et al., 2016) . Furthermore, aspirin, which is administered clinically to prevent pre-eclampsia, has been shown to reduce sFLT-1 levels, including those of the placental-specific variant .
Interestingly, a rise in serum sFLT-1 levels appears to precede the onset of clinical disease, with levels significantly higher than normal 5 weeks prior to the clinical diagnosis of pre-eclampsia (Levine et al., 2004; Powers et al., 2005) . This provides encouragement for the use of sFLT-1 levels in serum to predict the disease.
sFLT-1 acts as a VEGF trap sFLT-1 belongs to the VEGF/VEGFR family; a family which plays a vital role in angiogenesis and vasculogenesis. sFLT-1 was first identified by Kendall and Thomas (1993) , who described a soluble version of the fms-like tyrosine kinase-1 (FLT-1) receptor in the media of HUVECs. This was a time of rapid scientific advancement in the understanding of angiogenesis; with both VEGF and the full-length membrane-bound FLT-1 receptor (VEGFR-1) only identified in the preceding 4 years (Leung et al., 1989; Shibuya et al., 1990) . sFLT-1 is transcribed from the FLT-1 gene, which is located on chromosome 13q12. The translated sFLT-1 protein is identical to the majority of the extracellular region of FLT-1, containing the first six out of seven Ig-like domains. This is important, as the ligand-binding domain (second and third Ig-like domains) is conserved, enabling both FLT-1 and sFLT-1 to bind VEGF and PlGF with high affinity (Kendall et al., 1994; Park et al., 1994; Wiesmann et al., 1997; Christinger et al., 2004) . Furthermore, the presence of the fourth Ig-like domain conserves the ability for receptor dimerization and heparin binding (Wiesmann et al., 1997; Park and Lee, 1999) . The presence of sFLT-1 in vivo was subsequently confirmed in the placenta and serum of pregnant women with preeclampsia (Clark et al., 1998) , where its presence antagonized the actions of VEGF.
VEGF plays a crucial role in angiogenesis and normal endothelial cell function. Its bioavailability is strictly regulated and alterations in its circulating levels have a negative impact on endothelial cell function. This is highlighted by the drastic phenotypes exhibited through the effects of both under-and over-expression of VEGF on endothelial cell function in the kidney. Mice lacking Vegf solely within the podocytes (a vital component of the glomerular basement membrane) die within 18 hours of birth due to hydrops, renal failure and abnormal glomeruli (Eremina, 2003) . Podocytes with heterozygous Vegf expression are able to develop an appropriate glomerular filtration barrier (Eremina, 2003) ; however, their function is impaired with mice developing endotheliosis (similar to that seen in pre-eclampsia) by 2.5 weeks of age. These data support the premise that a reduction in VEGF bioavailability in the kidney is capable of producing proteinuria (Eremina et al., 2008) . If reduced VEGF levels are maintained, gradual progression to nephrotic syndrome with significant glomerular scarring occurs and eventual loss of podocytes by 9 weeks of age (Eremina, 2003) . Similarly, a 2-fold increase in podocyte VEGF expression also produces a dramatic phenotype with mice developing collapsing glomerulonephropathy, leading to death by 5 days of age (Eremina, 2003) .
The use of VEGF antagonists, such as bevacizumab, in the treatment of cancer has also highlighted the importance of VEGF in maintaining vascular homoeostasis (Maharaj and D'Amore, 2007) . The principal side effects seen are hypertension and proteinuria; however arterial thrombosis, cardiac ischaemia, gastrointestinal perforation, impaired wound healing and reversible posterior leukoencephalopathy syndrome have all been reported (Glusker et al., 2006; Ozcan et al., 2006; Kandula and Agarwal, 2011) . The significant overlap between the side effects of VEGF inhibitors and the features of pre-eclampsia provides strong circumstantial evidence of the importance of VEGF in pre-eclamptic pathophysiology. This rationale has been confirmed in vivo, where sFLT-1 administration led to the development of hypertension in rodent models (Maynard et al., 2003; Kumasawa et al., 2011) . This is thought to be due to reduced nitric oxide and prostacyclin production, both of which are regulated by VEGF (He et al., 1999a; Venkatesha et al., 2006) .
It can now be appreciated how excessive production of sFLT-1, as seen in pre-eclampsia, acts as a VEGF trap to cause the clinical features of disease. Through reducing VEGF bioavailability, sFLT-1 negatively impacts on both microvascular tone and endothelial cells within the glomerulus, causing hypertension and proteinuria.
The many variants of sFLT-1 sFLT-1 results either from alternative splicing of the FLT-1 pre-mRNA (He et al., 1999b) or through cleavage of the ectodomain of FLT-1 (Rahimi et al., 2009) . Proteolytic cleavage of the extracellular region is thought to occur adjacent to the transmembrane domain (Raikwar et al., 2016) and is potentially due to the actions of proteolytic enzymes, such as ADAM10, ADAM17 or MMP-14 (Raikwar et al., 2014; Han et al., 2015) . Proteolytic cleavage produces an sFLT-1 that is identical to the extracellular region of FLT-1, while the multiple variants of sFLT-1 that have been identified all have unique C-terminal sequences (Sela et al., 2008; Heydarian et al., 2009; Thomas et al., 2009) . The significance of these different splice variants currently remains unknown.
Alternative splicing has been found to occur in >80% of genes in the human genome with the majority of splicing events affecting the coding sequence (Matlin et al., 2005) . Splicing events are regulated by cis-and trans-elements. The former are sequences within the premRNA that help to direct splicing, such as exon splicing enhancers or silencers (ESEs or ESSs, respectively) and their intronic counterparts (ISEs and ISSs), as well as polyadenylation signals within the sequence. Trans-elements are cellular factors such as RNA or protein that regulate splicing. For example, the SR family of RNA-binding proteins bind to ESEs and assist in the assembly of the spliceosome complex (Matlin et al., 2005) .
The FLT-1 gene encodes an mRNA transcript containing 30 exons. The FLT-1 pre-mRNA has been shown to give rise to the full-length membrane-bound FLT-1, as well as four truncated soluble splice variants (Fig. 1 ). Of these, three sFLT-1 variants appear to be translated into protein, two of which are up-regulated in pre-eclamptic placenta (Heydarian et al., 2009) . The two variants altered in the setting of preeclampsia are sFLT-1 i13 (also known as sFLT-1; sFLT-1_v1 (Heydarian et al., 2009) ) and sFLT-1 e15a (also known as sFLT-1_v2 (Heydarian et al., 2009) ; sFLT-1 14 (Sela et al., 2008) ). As shown in Fig. 1 , these splice variants share significant sequence homology with the full-length FLT-1 receptor, differing only at their C-terminus.
sFLT-1 i13 was the first sFLT-1 identified (Kendall and Thomas, 1993) and comprises the first 13 exons of FLT-1 with an extension of exon 13 into the intronic sequence due to a read through of the exon 13-14 splice site (Heydarian et al., 2009; Thomas et al., 2009) . Intron 13 contains two widely separated polyadenylation signal sequences that are cis-elements regulating the alternative splicing of the i13 variant. This produces either a short or long 3′-untranslated region (UTR) depending on which polyadenylation sequence is utilized (Thomas et al., 2007) . The impact of alterations in the 3′-UTR is currently unknown, but has been suggested to possibly regulate mRNA expression in a tissue-specific or temporal fashion, or influence mRNA stability or its translational efficiency (Thomas et al., 2007) . As a result, after 657 amino acids, the i13 protein diverges from full-length FLT-1, encoding a unique 31 amino acid C-terminal tail and producing an 85-95 kDa protein.
In comparison, sFLT-1 e15a was identified more recently (Thomas et al., 2007) . Interestingly, it appears this variant is specific to humans and higher order primates, having resulted from the insertion of an AluSq sequence into the primate genome following a retrotransposition event~40 million years ago (Thomas et al., 2009) . Alu sequences are common and represent 6-13% of human genomic DNA (Mighell et al., 1997) . They are commonly found within intronic and non-coding DNA; however, they are capable of affecting gene transcription. They contain many stop codons and can also affect splicing to produce truncated proteins. Through their impact on splicing, they have been linked to a number of human diseases, such as neurofibromatosis, Alport syndrome and familial hypercholesterolaemia (Mighell et al., 1997) . Similarly, the introduction of the AluSq sequence leading to alternative sFLT-1 splicing could have contributed to the appearance of preeclampsia, a disease that is unique to humans and perhaps some higher order primates (Thornton and Onwude, 1992) .
sFLT-1 e15a arises from the use of a previously unknown splice acceptor site within intron 14 producing a protein consisting of the first 14 exons of FLT-1 followed by a 480 nucleotide stretch of intronic sequence (Sela et al., 2008) . This encodes the unique alternatively spliced exon 15a followed by a 3′-UTR containing the complete AluSq sequence. A polyadenylation signal sequence inserted as a result of the Alu sequence likely directs the alternative splicing of exon 15a, which encodes a unique polyserine tail (Thomas et al., 2007) . The resulting protein shares 706 amino acids with FLT-1 and has a unique 28 amino acid tail, producing a protein that is 95-135 kDa in size due to variations in the level of glycosylation (Gu et al., 2008) . Importantly, sFLT-1 e15a is absent from all mammals except humans and higher order primates, highlighting it as potentially the key variant underlying preeclamptic pathophysiology.
sFLT-1 splice variant mRNA expression and regulation Both sFLT-1 i13 and sFLT-1 e15a are capable of binding to VEGF and antagonizing its actions (Kendall et al., 1994; Sela et al., 2008; Palmer et al., 2015) . The i13 variant is also known to antagonize PlGF (Kendall et al., 1994) and it is likely the e15a variant does too, given the preservation of the ligand-binding site. Interestingly, the e15a variant is the predominant isoform in human placenta compared to i13, which is the main variant in rhesus monkey placenta (Thomas et al., 2009) . Furthermore, in humans sFLT-1 e15a appears to be almost exclusively expressed by the placenta where its expression is ≥600-fold higher than in the other organ systems where it is found (Jebbink et al., 2011) . Certainly within the placenta, sFLT-1 e15a is the predominant isoform of FLT-1 mRNA, constituting >80% of transcripts compared to sFLT-1 i13, which constitutes 12%, and membrane-bound FLT-1, which is <5% (Jebbink et al., 2011) . There are many extra-placental sources of sFLT-1 (He et al., 1999b; Jebbink et al., 2011) , which are likely to mainly be the i13 isoform as it is widely expressed throughout the body Suwaki et al., 2006; Souders et al., 2015) . However, with the exception of human brain microvascular endothelial cells, it is always expressed to a lesser extent than the membrane-bound FLT-1 (Jebbink et al., 2011) . While this suggests a tissue-specific expression profile of FLT-1 transcripts, expression also appears to be cell-type specific. In blood vessels, endothelial cells appear to exclusively produce the i13 variant, whereas the underlying vascular smooth muscle exclusively expresses the e15a variant (Sela et al., 2008) . Furthermore, there is the potential for temporal regulation of expression, as splicing patterns have been shown to alter over the course of pregnancy in mice. In murine placenta, Flt-1 predominates early in gestation before sFlt-1 becomes more highly expressed from the second trimester onwards (He et al., 1999b) . Whether this holds true in humans remains to be fully characterized; however, it is possible given the rise in circulating sFLT-1 seen with advancing gestation (Levine et al., 2004; Palmer et al., 2015) .
Within the placenta, sFLT-1 e15a is mainly produced by the syncytiotrophoblast and cytotrophoblast, where its mRNA expression is 100-fold greater than in placental vascular smooth muscle cells, endothelial cells and macrophages (Thomas et al., 2009 ). In the setting of pre-eclampsia, all FLT-1 transcripts appear up-regulated (Jebbink et al., 2011) ; however, sFLT-1 e15a shows the greatest increase, with levels appearing to correlate with severity of pre-eclampsia (Whitehead et al., 2011) .
Placental hypoxia is a key factor in pre-eclamptic pathophysiology. Many transcriptional regulators have been shown to be involved in increasing the expression of both FLT-1 and sFLT-1 in response to hypoxia, such as hypoxia inducible factor (Gerber et al., 1997; Nagamatsu et al., 2004; Tal et al., 2010) , growth arrest and DNA damage 45 (Xiong et al., 2009 ) and early growth response protein 1 (Vidal et al., 2000) . Similarly, many key molecules in the hypoxic response also increase the expression of sFLT-1, such as VEGF (Gerber et al., 1997) and adenosine through the up-regulation of a key enzyme, CD73 well as the four soluble alternative sFLT-1 splice variants. All transcripts are identical to exon 13, with the soluble transcripts each identified by a unique C-terminal region. Of these, sFLT-1 i13, sFLT-1 e15a and sFLT-1 v4 are translated into protein with only the former two being increased in preeclampsia. Reprinted with permissions from Palmer et al. (2015) . (Iriyama et al., 2015) . Furthermore, the mechanism controlling the regulation of alternative splicing of FLT-1 also appears to be hypoxia dependent. Recently, it has been shown that a nuclear protein, known as jumonji domain containing protein-6 (JMJD6) is a regulator of alternative splicing of the FLT-1 pre-mRNA (Boeckel et al., 2011) . Under normoxic cellular conditions, JMJD6 is able to interact with a component of the spliceosome complex, U2AF65, hydroxylating it. Hydroxylated U2AF65 then directs the splicing machinery to produce full-length FLT-1. Importantly, they were able to show that under hypoxic conditions, there was inhibition of the interaction of JMJD6 and U2AF65, as JMJD6 requires oxygen for its enzymatic function. Under these conditions, within endothelial cells, non-hydroxylated U2AF65 directed splicing to produce sFLT-1 (Boeckel et al., 2011) . We have recently shown this mechanism of FLT-1 splicing also occurs within the placenta, where the silencing of JMJD6 expression or the effects of hypoxia led to an up-regulation of both sFLT-1 i13 and sFLT-1 e15a (Palmer et al., 2016b) . Importantly, it was also noted that the expression of JMJD6 is significantly reduced in the pre-eclamptic placenta, likely secondary to the effects of hypoxia (Palmer et al., 2016b) .
With an increased understanding of the pathophysiology of preeclampsia, many are now actively seeking new therapies that could provide an alternative to delivery. A number of drugs under investigation have also explored their effect on sFLT-1 variant mRNA expression, as outlined in Table I . Interestingly, in vitro treatment with both YC-1 and pravastatin led to a significant reduction solely in sFLT-1 e15a mRNA expression with no significant effect seen on the sFLT-1 i13 variant (Brownfoot et al., 2015a,b) . Metformin led to a significant reduction in sFLT-1 i13 mRNA expression in endothelial cells and sFLT-1 e15a mRNA expression from cytotrophoblast and placental explants (Brownfoot et al., 2016) , while treatment with ouabain led to a significant reduction in both sFLT-1 i13 and e15a variant expression in placental explants, though with a trend towards greater repression of the e15a variant (Rana et al., 2014) . These findings all support the importance of sFLT-1 in pre-eclampsia and potentially that targeting therapies that reduce the placental-specific variant is crucial for effectively reducing circulating sFLT-1 in early-onset pre-eclampsia.
The impact of circulating sFLT-1 e15a
While many studies have assessed altered mRNA expression of the sFLT-1 splice variants, limited work has been undertaken on the protein due to a lack of any commercially available assay. Furthermore, as detailed above, each splice variant has a very small unique tail against which antibodies can be developed to ensure specificity for the [Drug], drug concentration; TNF, tumour necrosis factor; NS, not significant; N/A, not available; HIF-1α, hypoxia inducible factor 1α; HSP27, heat-shock protein 27; NO, nitric oxide; PET, pre-eclampsia; FCS, foetal calf serum; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase and CTB, cytotrophoblast. All cells tested were cultured under standard conditions at 37°C in 5% CO 2 with oxygen conditions as stated. *All statistically significant changes refer to a decrease in sFLT-1 variant mRNA expression in experimental groups compared to control treated cells. A t-test was used for statistical analysis in all studies.
particular sFLT-1 splice variant of interest. These antibodies, developed in the non-commercial setting, enable the assessment of how the translated sFLT-1 proteins function and their expression in both health and disease (see Fig. 2 ). We have developed an ELISA that specifically detects the sFLT-1 e15a variant (Palmer et al., 2015) . This involved developing a peptide sequence from the unique tail of the variant protein ( Fig. 2; boxed  sequence) . This peptide was then coupled to a highly immunogenic protein for animal immunization. Once an appropriate antibody response had occurred, polyclonal antibodies were isolated from the serum and purified for testing. Importantly, both the antibody and the subsequent sFLT-1 e15a ELISA that was developed are specific to this isoform. Importantly, an independent group has also successfully developed monoclonal antibodies targeting both sFLT-1 i13 and a peptide sequence seen in FLT-1, sFLT-1 e15a, sFLT-1_v3 and sFLT-1_v4 (Souders et al., 2015) (Fig. 2; underlined sequences) . As it is used on serum, Souders et al. believe it will be relatively specific for sFLT-1 e15a due to the membrane-bound nature of FLT-1 and the exceptionally low expression of the other sFLT-1 splice variants. However, cleavage of FLT-1 to produce a cleaved soluble version is also possible, which may impact on the specificity of this antibody (Raikwar et al., 2014) .
Using these novel systems, both groups have shown that sFLT-1 e15a gradually rises with advancing gestation (Palmer et al., 2015; Souders et al., 2015) and is significantly elevated in women who go on to develop pre-eclampsia and in those diagnosed with the early-onset form (Palmer et al., 2015 (Palmer et al., , 2016a Souders et al., 2015) . Interestingly, the sFLT-1 i13 variant is the one most significantly increased in women who develop pre-eclampsia >34 weeks gestation (Souders et al., 2015; Palmer et al., 2016a) , perhaps due to widespread maternal endothelial dysfunction, thought to be the main contributor to late-onset pre-eclampsia.
Encouragingly, we have also determined that the sFLT-1 e15a variant protein is biologically active, being capable of antagonizing the actions of VEGF (Palmer et al., 2015) . Endothelial cell function is also impacted by the sFLT-1 splice variants, with evidence of impaired endothelial cell invasion, migration and tubule formation in the presence of either sFLT-1 i13 or sFLT-1 e15a (Palmer et al., 2015) . Importantly, normal VEGF signalling and endothelial function were maintained with the addition of heat inactivated sFLT-1 e15a (Palmer et al., 2015) . Furthermore, the over-expression of the sFLT-1 e15a variant in mice produces a pre-eclamptic phenotype, regardless of whether an adenoviral (Szalai et al., 2014 (Szalai et al., , 2015 or lentiviral (Kumasawa et al., 2011) expression system is used. In combination, these works confirm the ability of the sFLT-1 e15a protein to cause endothelial dysfunction and the clinical features of pre-eclampsia. It is also possible that sFLT-1 e15a expression is altered in other conditions of placental malfunction, such as foetal growth restriction (Palmer et al., 2016a) , although this requires further investigation.
Implications for clinical practice
The discovery of multiple sFLT-1 splice variants provides the potential to better identify disorders of placentation through targeting strategies towards the placental-specific variant, sFLT-1 e15a.
The use of both anti-angiogenic and angiogenic factors as biomarkers for the prediction or diagnosis of pre-eclampsia was identified as soon as their importance in the disease process was realized (Hertig et al., 2004) . Subsequent work has shown that total sFLT-1, particularly as a ratio with PlGF, appears able to diagnose and even predict the development of early-onset pre-eclampsia (Schiettecatte et al., 2010; Benton et al., 2011; Verlohren et al., 2012; Villa et al., 2013; Liu et al., 2015; Andersen et al., 2016; Zeisler et al., 2016) . However, the diagnostic accuracy of this test for late-onset pre-eclampsia remains poor. This test is yet to be widely integrated into clinical practice and recent work shows that the test performs better as a negative predictor of early-onset pre-eclampsia rather than being able to accurately predict who will develop the disease (Zeisler et al., 2016) .
As these tests detect total sFLT-1, their accuracy may be hampered by the presence of both cleaved and alternatively spliced sFLT-1, particularly sFLT-1 i13 that has a strong endothelial source. For example, accurate diagnosis of early-onset pre-eclampsia may be limited when using total sFLT-1 levels in women with pre-existing endothelial dysfunction (such as obesity and diabetes) who do not have pre-eclampsia due to increased endothelial secretion of sFLT-1 i13. Therefore, developing a test that solely detects the placental-specific sFLT-1 variant, sFLT-1 e15a, may have improved accuracy in disorders of placental function, such as early-onset pre-eclampsia. Furthermore, the ability to detect the different splice variants of sFLT-1 may also provide better accuracy for detecting term pre-eclampsia. As term pre-eclampsia likely results from underlying maternal endothelial dysfunction rather than placental disease, a test that can distinguish between the cellular origins of sFLT-1 may be more accurate. Here, potentially a ratio of sFLT-1 e15a to sFLT-1 i13 may be useful. For example, in early-onset pre-eclampsia, the ratio would be higher (e15a > i13), because the e15a variant is likely to have greater expression than the i13 variant. In comparison, in late-onset pre-eclampsia, the ratio would be lower (e15a < i13), as widespread endothelial dysfunction is likely to cause a greater expression of the i13 variant to the e15a variant. Preliminary data support this supposition, where no significant increase in sFLT-1 e15a is seen in term disease, while total sFLT-1 is significantly increased (Palmer et al., 2016a) . Moreover, this
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650 kkeiƟrdqeapyllrnlsdhtvaisssƩldchangvpepqitwŅnnhkiqqepgiilgpgsstlfiervtee… sFLT-1 i13 650 kkeiƟrgehcnkkavfsriskŅstrndcƩqsnvkh sFLT-1 e15a 650 kkeiƟrdqeapyllrnlsdhtvaisssƩldchangvpepqitwŅnnhkiqqepelytstspsssssspls [11] Figure 2 Alignment of the amino acid sequence for human FLT-1, sFLT-1 i13 and sFLT-1 e15a. The amino acid sequence for all proteins is shown from amino acid 650: sequence prior to amino acid 650 shares 100% homology between the three proteins. The unique C-terminal tails are highlighted for sFLT-1 i13 and sFLT-1 e15a (grey). Antibodies that have been developed are indicated with the underlined sequences indicating those used by Souders et al. (2015) and the boxed sequence by Palmer et al. (2015) . The sFLT-1 e15a polyserine tail continues for a further 11 serine residues. premise is strongly supported by the fact that those developing term pre-eclampsia have an average 3-fold increase in circulating sFLT-1 levels compared to normal term controls, whereas a 43-fold increase in serum sFLT-1 is seen in early-onset disease compared to preterm controls (Wikstrom et al., 2007) . However, this remains an area requiring further investigation as studies performed to date on lateonset pre-eclampsia were limited by a small sample size. Furthermore, research in this area is currently limited by the absence of any commercially available assays.
Discussion
Pre-eclampsia remains a significant burden to women and their healthcare providers globally, being directly responsible for 14% of maternal deaths globally (Say et al., 2014) . While the bulk of the maternal mortality is sadly in developing countries, pre-eclampsia remains a major cause of maternal mortality even in the developed world (Johnson et al., 2014) . The rapid advancement in our understanding of how preeclampsia arises, however, offers hope through aiding the development of new approaches to improve how we predict, diagnose and treat it. The discovery of multiple different splice variants of sFLT-1 has led to the finding of a placental-specific variant, sFLT-1 e15a (Sela et al., 2008; Heydarian et al., 2009; Thomas et al., 2009) . This splice variant is seen only in humans and is principally expressed in the placenta (Jebbink et al., 2011) , making it likely to be the variant chiefly responsible for the clinical features of early-onset pre-eclampsia.
Importantly, the sFLT-1 e15a variant has been shown to be biologically active and capable of producing endothelial dysfunction (Palmer et al., 2015) . Furthermore, sFLT-1 e15a is significantly elevated in women with preterm pre-eclampsia (<34 weeks gestation), with levels elevated prior to the onset of clinical symptoms (Palmer et al., 2015 (Palmer et al., , 2016a Souders et al., 2015) . It is also significantly reduced by a number of therapeutic agents that show promise as new drugs with which to treat pre-eclampsia (Rana et al., 2014; Brownfoot et al., 2015a Brownfoot et al., , b, 2016 .
The sFLT-1 variants, with their differing tissue specificity, therefore offer a unique opportunity to capitalize on the potential of sFLT-1 as a predictive or diagnostic marker of pre-eclampsia. Development of accurate assays to measure these variants may significantly improve test performance (both in combination with PlGF or alone) for both early and late-onset disease. The development of an accurate test could significantly advance the delivery of obstetric care globally without increasing the economic burden on already financially challenged healthcare systems . Furthermore, in better understanding the pathways involved in the release of anti-angiogenic factors from the placenta and the role the different splice variants play, it may assist in improved therapeutic design and assessment of drug effectiveness.
